证券之星消息，8月11日化学制药板块较上一交易日上涨1.29%，天宇股份领涨。当日上证指数报收于 3647.55，上涨0.34%。深证成指报收于11291.43，上涨1.46%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | | --- | --- | --- | --- | --- | --- | --- | | 300702 | 天宇股份 | 29.77 | 14.50% | 26.66万 | | 7.87亿 | | 300436 | 广生堂 | 132.81 | 11.70% | 16.11万 | | 20.37亿 | | 603538 | 美诺华 | 28.68 | 10.01% | 51.47万 | | 14.26 乙 | | 002826 | 易明医药 | 22.81 | 9.98% | 19.74万 | | 4.38亿 | | 300255 | 常山药业 | 44.46 | 8.52% | 55.73万 | | 24.31亿 | | 300233 | 金城医药 | 19.14 | 7.65% | 57.97万 | | 10.9 ...

通过天眼查大数据分析，西藏易明西雅医药科技股份有限公司共对外投资了6家企业，参与招投标项目 10次，知识产权方面有商标信息11条，专利信息16条，此外企业还拥有行政许可15个。 金融界消息 截至2025年8月5日收盘，易明医药（002826）报收于21.34元，下跌3.09%，换手率7.74%， 成交量13.49万手，成交金额2.89亿元。 来源：金融界 易明医药最新一期业绩显示，截至2025一季报，公司营业总收入1.49亿元、同比减少7.41%，归属净利 润1879.39万元，同比减少32.64%，扣非净利润1023.54万元，同比增长475.03%，流动比率2.781、速动 比率2.625、资产负债率22.20%。 天眼查商业履历信息显示，西藏易明西雅医药科技股份有限公司，成立于2007年，位于拉萨市，是一家 以从事批发业为主的企业。企业注册资本19067.775万人民币，实缴资本7491.4792万人民币。公司法定 代表人为许可。 资金流向方面，今日主力资金净流出2334.51万元，占比成交额8.07%。其中，超大单净流出815.08万 元、占成交额2.82%，大单净流出1519.43万元、占成交额5. ...

New Stock Listings - HanGao Group listed on July 30, 2025, with an issue price of 15.43[1] - *ST Zitian and *ST Suwu are under severe abnormal fluctuations as of July 30, 2025[1] - Tianlu Convertible Bonds listed on July 30, 2025, with a risk warning[1] Market Alerts - Multiple stocks including *ST Xinchao and *ST Yuancheng are flagged for severe abnormal fluctuations on July 30, 2025[1] - New listings include companies like Xianghe Precision and Shenshui Planning, with announcements made on July 30, 2025[1] - The report includes links to detailed announcements for each stock, ensuring transparency and accessibility for investors[1] Trading Insights - The report highlights the importance of monitoring newly listed stocks for potential volatility and investment opportunities[1] - Investors are advised to review the latest announcements and risk warnings associated with these stocks to make informed decisions[1]

Core Viewpoint - The announcement highlights the recent abnormal stock price fluctuations of Tibet Yiming Xiya Pharmaceutical Technology Co., Ltd. and the ongoing changes in control due to a share transfer agreement with Beijing Fuhai [2][3][4]. Group 1: Stock Trading Abnormalities - The stock of Tibet Yiming Xiya Pharmaceutical experienced a cumulative price deviation of over 20% across three consecutive trading days on July 23, 24, and 25, 2025, indicating abnormal trading activity [3]. - The company confirmed that there were no undisclosed significant matters affecting the stock price and that the operational environment remains stable [4][5]. Group 2: Share Transfer Agreement - On May 31, 2025, a share transfer agreement was signed between the controlling shareholder Gao Fan and Beijing Fuhai, involving the transfer of 43,855,883 shares, which represents 23.00% of the total shares of the company [4]. - A supplementary agreement to the share transfer was signed on July 25, 2025, with further details disclosed in a subsequent announcement [2][4]. Group 3: Compliance and Future Reporting - The company is awaiting compliance confirmation from the Shenzhen Stock Exchange regarding the share transfer and must complete the necessary procedures for share registration [5]. - The company plans to disclose its 2025 semi-annual report on August 15, 2025, and is currently preparing the financial data [5].

Group 1 - The company, Tibet Yiming Xiya Pharmaceutical Technology Co., Ltd., announced a significant change in control due to a share transfer agreement signed between the controlling shareholder Gao Fan and Beijing Fuhai, involving the transfer of 43,855,883 shares, which represents a substantial portion of the company's total shares [3][4]. - The company's stock experienced abnormal trading fluctuations, with a cumulative price deviation exceeding 20% over three consecutive trading days from July 23 to July 25, 2025 [2]. - The board of directors confirmed that there are no undisclosed significant matters or ongoing negotiations that would require disclosure under the Shenzhen Stock Exchange regulations, ensuring transparency in the company's operations [4][5]. Group 2 - The company is currently in the process of preparing its semi-annual report, and as of now, it has not reached the threshold that would necessitate a performance forecast disclosure according to the Shenzhen Stock Exchange rules [5]. - The company will continue to adhere strictly to legal and regulatory requirements regarding information disclosure and will ensure timely updates to stakeholders [4].

本次权益变动事项尚需取得深圳证券交易所的合规性确认意见并在中国证 券登记结算公司深圳分公司办理股份过户登记手续以及完成相关法律法规要求 可能涉及的其他批准，该事项能否最终实施完成及实施结果尚存在不确定性， 敬请投资者注意投资风险； 2、公司股票价格近期波动较大，存在短期市场情绪过热的情形，可能存在 非理性交易行为，交易风险较大。敬请广大投资者注意交易风险，理性决策， 审慎判断投资价值。 一、 股票交易异常波动的情况介绍 西藏易明西雅医药科技股份有限公司股票（证券代码：002826，证券简 称：易明医药）于2025年7月23日、2025年7月24日、2025年7月25日连续三个交 1 易日内日收盘价涨幅偏离值累计达到20％以上，根据深圳证券交易所的相关规 定，属于股票交易异常波动的情况。 证券代码：002826 证券简称：易明医药 公告编号：2025-051 西藏易明西雅医药科技股份有限公司 股票交易异常波动公告暨风险提示公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 重要风险提示： 1、西藏易明西雅医药科技股份有限公司（以下简称"公司"或"本公司"） 于 ...

Group 1 - The core point of the news is the transfer of control of Xizang Yiming Xiya Pharmaceutical Technology Co., Ltd. from Gao Fan to Beijing Fuhao Enterprise Management Partnership, with Beijing Fuhao acquiring 23.00% of the company's shares [1][2] - Following the completion of the equity transfer, Beijing Fuhao will hold 43,855,883 shares, making it the new controlling shareholder, while the actual controller will change to Yao Jinbo [1][2] - A supplementary agreement has been signed to address unfulfilled matters from the main agreement, including performance commitments and recovery of funds related to a previous investment [2]

证券代码：002826 证券简称：易明医药 公告编号：2025-050 西藏易明西雅医药科技股份有限公司 关于控制权拟发生变更的进展暨签署补充协议的公告 高帆保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。本公司及董事会全体成员保证公告内容与信息披露 义务人提供的信息一致。 一、本次权益变动的情况 2025 年 5 月 31 日，西藏易明西雅医药科技股份有限公司（以下简称"上市 公司"、"公司"）控股股东、实际控制人高帆与北京福好企业管理合伙企业（有 限合伙）（以下简称"北京福好"、"受让方"）签署了《股份转让协议》（以 下简称"主协议"），北京福好拟协议收购高帆持有的 43,855,883 股公司股份， 占上市公司股份总数的 23.00%。 本次权益变动完成后，北京福好将持有公司 43,855,883 股股份（占上市公司 股份总数的 23.00%），公司控股股东将由高帆变更为北京福好，实际控制人将 由高帆变更为姚劲波。 1、就公司控股子公司内蒙古博斯泰企业管理服务有限责任公司原股东王键 泽（简称"业绩承诺方"）业绩承诺事项，转让双方应配合并促使公司要求业绩 承诺方实际履行业 ...

Group 1: Stock Performance - Yiming Pharmaceutical achieved a 10.00% increase over two consecutive days, driven by developments in Tibet and medical technology [3] - Kantai Medical saw a first board listing with a 20.03% rise, attributed to medical device advancements [4] - Zhengchuan Co. also debuted on the first board with a 9.99% increase, linked to medicinal glass [3] - Yuheng Pharmaceutical and Tianmu Pharmaceutical both recorded first board listings with increases of 10.09% and 10.00% respectively, related to the pharmaceutical sector [3] Group 2: AI and Robotics - Zhi Zhen Technology and Zhongdian Xinlong both debuted on the first board with a 10.01% increase, associated with computing power and machine learning [6] - Hubei Broadcasting and Duolun Technology also saw first board listings with increases of 10.04% and 9.95%, driven by computing power and AI applications [7] - The M-Robots open-source project was announced, aiming to create a unified robot operating system [11] Group 3: Infrastructure and Energy - The announcement of a 1.2 trillion yuan investment in a super hydropower project has led to significant interest in related stocks [13][16] - Nanfang Road Machinery and Tuoshan Heavy Industry both achieved consecutive board listings with increases of 9.99% and 10.01%, linked to engineering machinery [15] Group 4: Tourism and Hospitality - The demand for various types of tourism, including educational and family trips, has surged, with national railways reporting 341 million passenger trips [18][19] - Sizhizang Tourism and Tianfu Cultural Tourism both recorded first board listings with increases of 9.99% and 10.04%, reflecting the growing tourism sector [20] Group 5: Market Trends - The stock market has shown a strong focus on sectors such as robotics, AI, and infrastructure, with multiple companies achieving significant stock price increases [22][23]

Investment Rating - The report maintains a "Recommended" investment rating for the healthcare sector [7]. Core Insights - The healthcare sector has shown a mixed performance, with the Shenyin Wanguo Pharmaceutical Bio Index rising by 1.60% from June 23 to June 27, 2025, underperforming the CSI 300 Index by 0.35 percentage points [2][12]. - Year-to-date, the pharmaceutical sector has increased by 6.24%, outperforming the CSI 300 Index by 6.57 percentage points, ranking 11th among 31 sectors [2][14]. - As of June 27, 2025, the valuation of the pharmaceutical sector stands at 27.54 times (TTM overall method, excluding negative values), with a premium of 140.94% compared to the CSI 300 [2][17]. Summary by Sections 1. Market Performance - The pharmaceutical sector's performance from June 23 to June 27, 2025, was a 1.60% increase, ranking 23rd among 31 sectors [12]. - The year-to-date performance shows a 6.24% increase, ranking 11th among 31 sectors [14]. 2. Important Events - The National Healthcare Security Administration released the "2025 Basic Medical Insurance Directory and Commercial Insurance Innovative Drug Directory Adjustment Application Guidelines," marking a significant step for commercial health insurance in the multi-level medical security system [4][21]. 3. Industry Perspective - The inclusion of the commercial insurance innovative drug directory indicates an enhanced role for commercial insurance in the multi-level medical security system, providing greater opportunities for the industry [5][22]. - The report expresses optimism for innovative drugs, overseas expansion, and the clearing of procurement in specific segments, suggesting a focus on companies involved in these areas [22].